Mode
Text Size
Log in / Sign up
Phase 4 N=22 Randomized Single-blind Treatment

High Frequency Stimulation Trials in Patients With Precision Spinal Cord Stimulator System

Chronic Pain · Low Back Pain · Radiculopathy · Complex Regional Pain Syndrome (CRPS)

Enrolled (actual)
22
Serious AEs
0.0%
Results posted
Nov 2015
Primary outcome: Primary: Numeric Pain Rating Scale (NPRS) — 6.09; 6.27; 3.73; 3.82 units on a scale

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
High frequency stimulation (Other); Low frequency stimulation (Other)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
The Center for Clinical Research, Winston-Salem, NC
Primary completion
Jan 2015

Outcome Measures

OutcomeResultp-value
PRIMARY
Numeric Pain Rating Scale (NPRS)
6.09; 6.27; 3.73; 3.82; 5.64; 6.09
SECONDARY
Oswestry Disability Index Questionnaire (ODI).
47.49; 51.25; 39.23; 33.77; 49.63; 49.05
SECONDARY
Patient's Global Impression of Change (PGIC)
4.27; 5.91; 2.54; 2.45; 1.45; 1.27

Summary

Study designed to compare the conventional stimulation programming versus the high frequency stimulation programming of the spinal cord stimulator for subjects who already have a spinal cord stimulator.

Eligibility Criteria

Inclusion Criteria

  • Subject must be 18 years and older, and younger than 70 years of age.
  • Subject has had a Precision® spinal cord stimulator system implanted for chronic painful condition.
  • Subject pain scores >5 on NPRS

Exclusion Criteria

  • Currently diagnosed with cognitive impairment, or exhibits any characteristic, that would limit study candidate's ability to assess pain
  • Unstable medical or psychiatric illness
  • Lifetime history of psychosis, hypomania, or mania.
  • Epilepsy, or dementia
  • Substance abuse in the last 6 months
  • Pregnant or breastfeeding
  • Not on contraception for those of childbearing age. (Barrier methods, oral contraception, hormone injections, or surgical sterilization)
  • Treatment with investigational drug within 30 days of screening.
  • Concomitant medication exclusions consisting of medications or herbal agents with central nervous system (CNS) effects with exception of episodic use of sedating antihistamines
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02265848). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search